Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2010. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Share Price: £12.75 per Ordinary share.
- Transaction Type: Increase in interests following the re-investment of the dividend paid on April 8, 2010.
Material Changes
The filing details specific increases in shareholdings for the following individuals:
- Mr A P Witty: 862 shares
- Mrs C M Witty: 491 shares
- Mr J S Heslop: 257 shares
- Mr D Learmouth: 266 shares
- Dr D Pulman: 223 shares
- Mrs C R Pulman: 74 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Checklist
- Verify the total number of shares acquired by directors and connected persons via dividend re-investment.
- Confirm the share price of £12.75 used for the transaction on April 8, 2010.
- Review the full list of individuals whose holdings were updated in this notification.